ROBERT SUMMEROUR: Open Payments
NPI 1811085160 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,105 in 52 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $832 · 2025 $1,105
Food & beverage: $1,105
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $216 |
| Teva Pharmaceuticals USA, Inc. | 11 | $202 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $151 |
| Alkermes, Inc. | 7 | $141 |
| Otsuka America Pharmaceutical, Inc. | 4 | $96 |
| ABBVIE INC. | 4 | $86 |
| Janssen Pharmaceuticals, Inc | 2 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Almatica Pharma LLC | 1 | $27 |
| Lundbeck LLC | 1 | $22 |
Products named: INGREZZA, CAPLYTA, ARISTADA, AUSTEDO XR, REXULTI, VRAYLAR, UZEDY, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
